Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin or Carboplatin in Metastatic TNBC
NCT00483223Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2007
- Primary completion
- Jun 2014
- Modality
- Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cisplatin micelle injection (HA132) and carboplatin in triple-negative breast cancer (TNBC), sponsored by Massachusetts General Hospital. Primary endpoints: Objective Response Rate at 3 years and Response Rate Categorized by p63/p73 Ratio at 3 years. Started Jun 2007; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)carboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00483223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00483223.